HPC
TEVA icon

Highland Peak Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Highland Peak Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.02M Buy
+200,000
New +$6.43M 1.61% 13

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highland Peak Capital's TEVA Position: Q1 2026 in Review

Highland Peak Capital reduced its Teva Pharmaceuticals (TEVA) stake by 4.6% in Q1 2026, selling an estimated $659K and leaving 421,153 shares worth $12.7M. The position accounts for 3.4% of the portfolio, ranked #9.

Highland Peak Capital first reported a position in TEVA in Q2 2025 and has held it in 4 quarters since. The position peaked at $13.8M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Highland Peak Capital held 421,153 shares of Teva Pharmaceuticals worth $12.7M as of Q1 2026.
  • Highland Peak Capital sold 20,486 Teva Pharmaceuticals shares in Q1 2026, an estimated $659K.
  • Teva Pharmaceuticals made up 3.4% of Highland Peak Capital's portfolio in Q1 2026, its #9 holding.
  • Highland Peak Capital first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Highland Peak Capital's Teva Pharmaceuticals position peaked at $13.8M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Highland Peak Capital's 13F filing for Q1 2026, filed 13 May 2026.